DUX4-rearranged B-ALL has a unique immunophenotype (CD2 and CD371 positive), and a favorable outcome can be obtained, even with the deletion of IKZF1, by adjusting the intensity of the chemotherapy based on the MRD [31,32]. This evidence concerns the gene DUX4 and acute lymphoblastic leukemia.